Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Ambion granted license to fundamental RNAi patents
July 6th, 2005
Alnylam Pharmaceuticals, Inc., (ALNY) has granted Ambion, Inc., a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells. "This agreement with Ambion reflects the value and strength of the intellectual property portfolio owned by Alnylam," said Vincent Miles, PhD, senior VP, Business Development of Alnylam Pharmaceuticals. "With this agreement, Ambion, a recognized leader in the growing field of RNAi research products and services,...
Source: Biotech Week (2005-07-06)
|
